Shots:
- The company has expanded its Direct-to-Patient service offerings for supporting decentralized clinical trials to lessen clinical trial lengths and costs while increasing patient enrollment and participation rates
- The company’s expanded Direct-to-Patient services build on its global Clinical Site-to-Patient program that launched in early 2020 to ensure that clinical trial patients have uninterrupted access to life-saving drug shipments without visiting a clinic
- The Direct-to-Patient services include Pharmacy-to-Patient, Depot-to-Patient, and Clinical Site-to-Patient services, enabling clinical trial medication delivered directly to patients’ homes. Clinical Site-to-Patient services are available in 47 countries, supporting 1,500+ shipments to patients globally
Click here to read full press release/ article | Ref: PRNewswire | Image: Tele Trader
The post Thermo Fisher Expands its Direct-to-Patient Service Offerings first appeared on PharmaShots.
